1. Name and Address of Reporting Person*  
Karnani Vikram  
(First) (Last) (Middle)  
C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD  
DUBLIN L2 4  

2. Issuer Name and Ticker or Trading Symbol  
Horizon Therapeutics Public Ltd Co [ HZNP ]  

3. Date of Earliest Transaction (Month/Day/Year)  
01/21/2020  

4. If Amendment, Date of Original Filed (Month/Day/Year)  
01/21/2020  

5. Relationship of Reporting Person(s) to Issuer  
Director  
EVP, Chief Commercial Officer  

6. Individual or Joint/Group Filing (Check Applicable Line)  
Form filed by One Reporting Person  
Form filed by More than One Reporting Person  

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
<th>8. Price of Securities (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>01/21/2020</td>
<td></td>
<td>A(1)</td>
<td>5,353</td>
<td>A 83,499</td>
<td>D</td>
<td></td>
<td>$0.00</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>01/21/2020</td>
<td></td>
<td>F(2)</td>
<td>2,372</td>
<td>D 81,127</td>
<td>D</td>
<td></td>
<td>$38.25</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Restricted Stock Units (PSUs)</td>
<td>(2)</td>
<td>01/21/2020</td>
<td></td>
<td>A(3)</td>
<td>10,708</td>
<td>(1)</td>
<td>(1)</td>
<td>Ordinary Shares 10,708</td>
<td>$0.00</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**
1. On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022.  
2. Each PSU represents a contingent right to receive one ordinary share of the Issuer.

**Remarks:**

/s/ Miles W. McHugh,  
Attorney-in-Fact  
01/23/2020  

**Signature of Reporting Person Date**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.